Floatz logo

Hlcm051

Stroke, Acute

Healios K.K.Cell therapyPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

133 Active assets in the Stroke, Acute cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB

View all 50 →

Same molecule, other indications

Hlcm051 is also rated in:

ischemic strokeDormant
B
Indicative ·
56 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →